Vivesto AB (VIVE.ST)
SEK 0.23
(-2.34%)
SEK 0.23
(-2.34%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2022 | 5.18 Million SEK | 0.78% |
| 2021 | 5.14 Million SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 8.84 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | -100.0% |
| 2007 | 6.43 Million SEK | 0.0% |
| 2006 | - SEK | 0.0% |
| 2005 | - SEK | 0.0% |
| 2004 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 4.08 Million SEK | -14.19% |
| 2023 Q1 | 4.75 Million SEK | -8.2% |
| 2022 Q2 | 3.76 Million SEK | -13.06% |
| 2022 Q4 | 5.18 Million SEK | 50.52% |
| 2022 FY | 5.18 Million SEK | 0.78% |
| 2022 Q3 | 3.44 Million SEK | -8.51% |
| 2022 Q1 | 4.32 Million SEK | -15.83% |
| 2021 Q3 | 5.98 Million SEK | -13.62% |
| 2021 Q2 | 6.93 Million SEK | 107.23% |
| 2021 FY | 5.14 Million SEK | 0.0% |
| 2021 Q1 | 3.34 Million SEK | 0.0% |
| 2021 Q4 | 5.14 Million SEK | -14.14% |
| 2020 Q2 | 7.49 Million SEK | -15.24% |
| 2020 Q4 | - SEK | -100.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q3 | 6.29 Million SEK | -15.99% |
| 2020 Q1 | 8.84 Million SEK | -13.05% |
| 2019 Q4 | 10.17 Million SEK | -9.72% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | 8.84 Million SEK | 0.0% |
| 2019 Q2 | 12.58 Million SEK | 0.0% |
| 2019 Q3 | 11.26 Million SEK | -10.44% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | -100.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | 93.15 Million SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q4 | - SEK | -100.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | 105 Million SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | -100.0% |
| 2007 FY | 6.43 Million SEK | 0.0% |
| 2006 FY | - SEK | 0.0% |
| 2005 FY | - SEK | 0.0% |
| 2004 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | 80.342% |
| Enzymatica AB (publ) | 24.88 Million SEK | 79.179% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -1609.901% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | -49.438% |
| Nanexa AB (publ) | 2.08 Million SEK | -148.251% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | 98.845% |
| Probi AB (publ) | 38.21 Million SEK | 86.441% |
| Swedencare AB (publ) | 1.44 Billion SEK | 99.641% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.954% |
| Toleranzia AB | 850 Thousand SEK | -509.529% |